Seven Children’s Mercy Researchers Receive Funding from Masonic Cancer Alliance to Better Understand, Fight Pediatric Cancer
Seven researchers at Children’s Mercy Kansas City are the latest to receive Partners Advisory Board Funding grants from the Masonic Cancer Alliance (MCA), the outreach network of The University of Kansas Cancer. Each grant covers a project period of January 1, 2025-December 31, 2026.
Jacqelyn Nemechek, PhD, Hematology/Oncology/BMT, received a $250,000 grant for her project “Elucidating the Role of the Chromatin Reader ZMYND8 in Mediating Anti-Cancer Immunotherapy Through PD-L1.”
Read about Dr. Nemecheck's project
Taeju Park, PhD, Hematology/Oncology/BMT, received a $250,000 grant for his project “Inhibition of Glioblastoma Invasion Using CRK/CRKL-antagonist Peptides.”
Alexandra Prosser-Dombrowski, MD, Hematology/Oncology/BMT, received a $248,766 grant for her project “Defining Multi-omic Signatures of Developing and Established Infant Leukemia.”
Read about Dr. Prosser-Dombrowski's project
Laura Ramsey, PhD, Clinical Pharmacology and Toxicology, and Terrie Flatt, DO, MA, Hematology/Oncology/BMT, received a $250,000 grant for their project “Investigating Drug Metabolism in Hispanic Patients with Acute Lymphoblastic Leukemia.”
Read about Dr. Ramsey and Dr. Flatt's project
Jay Vivian, PhD, Clinical Genetics, received a $249,854 grant for his project “A Screen for Novel Small Molecules that Modulate Autophagy as a Therapy for Pediatric Leukemia.”
Read about Dr. Vivian's project
Vivekanand Yadav, PhD, Hematology/Oncology/BMT, received a $250,000 for his project “Novel Therapeutic Strategies for Diffuse Midline Glioma Using High-Throughput Combination Drug Screening.”
Read about Dr. Yadav's project
The Partners Advisory Board (PAB) is a collaboration between leadership teams from key MCA PAB member hospitals and research institutions. The PAB leverages regional strengths such as drug discovery and development and advancing cancer prevention, early detection, treatment, and survivorship to support and maintain KU Cancer Center’s National Cancer Institute comprehensive cancer center designation.